KLP Kapitalforvaltning AS Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

KLP Kapitalforvaltning AS acquired a new position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,600 shares of the biotechnology company’s stock, valued at approximately $41,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Teacher Retirement System of Texas bought a new position in shares of Astria Therapeutics in the 4th quarter worth $91,000. New York State Common Retirement Fund raised its position in Astria Therapeutics by 67.0% in the 4th quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Astria Therapeutics in the 4th quarter worth $107,000. SG Americas Securities LLC lifted its stake in Astria Therapeutics by 51.3% in the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 7,218 shares during the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Astria Therapeutics by 31.2% during the fourth quarter. Intech Investment Management LLC now owns 27,104 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 6,439 shares during the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Trading Down 0.5 %

NASDAQ:ATXS opened at $4.04 on Friday. The company has a 50-day moving average price of $6.09 and a 200-day moving average price of $8.57. The stock has a market cap of $227.99 million, a price-to-earnings ratio of -1.93 and a beta of 0.68. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. Equities analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wedbush restated an “outperform” rating and set a $28.00 target price (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. JMP Securities assumed coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $26.60.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.